SPY316.18+2.40 0.76%
DIA260.72+1.68 0.65%
IXIC10,492.50+148.61 1.44%

Cantor Fitzgerald Maintains Overweight on Aerie Pharmaceuticals, Lowers Price Target to $30

Cantor Fitzgerald maintains Aerie Pharmaceuticals (NASDAQ:AERI) with a Overweight and lowers the price target from $62 to $30.

Benzinga · -

Cantor Fitzgerald maintains Aerie Pharmaceuticals (NASDAQ:AERI) with a Overweight and lowers the price target from $62 to $30.